Unicorn Nest Logo

Delos Capital

deloscap.com
Type

Private equity

Status

Active

Location

New York, United States

Total investments

25

Average round size

63M

Portfolio companies

20

Rounds per year

2.27

Lead investments

5

Follow on index

0.20

Exits

2

Stages of investment
Private EquityLate Stage Venture
Areas of investment
BiotechnologyFitnessHealth CareHealth DiagnosticsManufacturingMedical DeviceMedicalPharmaceuticalTherapeuticsClinical Trials

Investor highlights

Industry focus
Deep TechManufacturingConsumer/RetailClimate techProptech/Real Estate

Discover reliable insights

Find relevant VC investors, identify key contacts and secure funding opportunities.

Find investors

Investments analytics

Analytics

Total investments
25
Lead investments
5
Exits
2
Rounds per year
2.27
Follow on index
0.20
Investments by industry
  • Biotechnology (15)
  • Health Care (13)
  • Therapeutics (8)
  • Medical Device (8)
  • Medical (7)
    • Show 24 more
Investments by region
  • United States (21)
  • China (3)
  • Germany (1)
Peak activity year
2021

Discover reliable insights

Leverage validated data, identify key contacts and secure funding opportunities for your business.
Sign Up

Quantitative data

Avg. startup age at the time of investment
10
Group Appearance index
0.92
Avg. company exit year
-4
Strategy success index
0.30

Need more data?

Get access to full data about investors, including their team, contact information, and historic data.

Upgrade

Latest deals

Company name Deal date Industry Deal stage Deal size Location
AltruBio 21 May 2024 Biotechnology, Health Care, Medical Early Stage Venture 225M United States, California
Rejoni 14 Sep 2020 Biotechnology, Health Care, Health Diagnostics, Medical Device Early Stage Venture 15M United States, Massachusetts, Bedford
How we get our data

At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).

Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.